Bempedoic acid (monotherapy) or bempedoic acid in combination with ezetimibe for primary hypercholesterolaemia or mixed dyslipidaemia
The current standard of care for patients with hypercholesterolaemia is primarily statins which are capable of reducing LDL-C. There is however a subset of patients who are unable to tolerate statins due to adverse effects. Bempedoic acid monotherapy or in combination with ezetimibe are once-daily tablets in development for patients unable to tolerate statins at all, or are not able to tolerate the necessary dose of statin required to reach their LDL-C goal, or are recommended not to use them due to various circumstances. Bempedoic acid and ezetimibe both act in complementary ways to lower LDL-C. These therapies may offer additional and effective treatment options to use in combination with dietary changes and other lipid-modifying therapies to treat primary hypercholesterolaemia or mixed dyslipidaemia.
Bempedoic acid for primary hypercholesterolaemia or mixed dyslipidaemia in patients unable to reach cholesterol goals with the maximum tolerated dose of a statin
Bempedoic acid lowers LDL-C via a different mechanism of action and offers the potential advantage of reduced muscular adverse effects when compared to statins which are the current standard of care. Bempedoic acid is being developed for patients at high cardiovascular risk who are unable to reach LDL-C goals with the maximum tolerated dose of statins. The effect of bempedoic acid is additive—not redundant—to that of statins, and if licensed, may offer additional and effective treatment option to use in combination with dietary changes and other lipid-modifying therapies to treat primary hypercholesterolaemia or mixed dyslipidaemia.
Beraprost modified release in addition to treprostinil for pulmonary arterial hypertension
Beraprost modified release, in addition to treprostinil, is in clinical development for the oral treatment of pulmonary arterial hypertension (PAH), a rare condition causing high blood pressure in the lungs. PAH can worsen over time and cause several problems including heart failure and blood clots. In PAH, the arteries in the lungs become thickened and …
Bempedoic acid (monotherapy) and bempedoic acid/ezetimibe (fixed-dose combination) for primary hypercholesterolaemia or mixed dyslipidaemia
Bempedoic acid and bempedoic acid combined with ezetimibe are once-daily tablets in development to treat primary hypercholesterolaemia or mixed dyslipidaemia in high risk and very high risk patients. These are patients who cannot reach the target LDL-C goals despite being treated with the maximum tolerated doses of other LDL-C lowering treatment such as statins. Bempedoic acid and ezetimibe both act in different but complementary ways to lower LDL-C. These therapies may offer additional and effective treatment options to use in combination with dietary changes and other lipid-modifying therapies to treat primary hypercholesterolaemia or mixed dyslipidaemia.
Ticagrelor for prevention of cardiovascular events in patients with type 2 diabetes mellitus who have coronary artery disease
Ticagrelor is an oral blood thinning medicine used together with aspirin to prevent problems caused by blood clots and hardening of the arteries that leads to heart attacks or strokes. Ticagrelor is in a class of medications called antiplatelet medications that help prevent blood clots from forming. It is used in adults with acute coronary syndrome, a group of conditions in which blood flow in the vessels supplying the heart is blocked so heart tissue cannot work properly or dies, and which includes heart attack and chest pain. If licensed, ticagrelor will offer an additional antiplatelet therapy for the prevention of CAD in patients with type 2 diabetes.
Tafamidis for Transthyretin Amyloid Cardiomyopathy
Tafamidis is an oral (taken by mouth) drug that has the potential to slow the formation of the amyloid deposits that can produce heart problems in people with ATTR‐CM. Tafamidis works by specifically interfering with the disease process that leads to the formation and deposition of the amyloids within the heart tissues. If approved, tafamidis will become the first medicinal treatment option specifically indicated for treating ATTR‐CM, in patients that currently have very limited options available and that mostly focus on symptom management.
Rivaroxaban for prevention of cardiovascular events following an episode of decompensated heart failure
Rivaroxaban is an oral medicine which prevents the development of blood clots by blocking the formation of a molecule called thrombin which is a key part of the process of blood clot formation. Rivaroxaban has the potential to reduce thrombin and blood clot formation in people with heart failure and coronary artery disease. This is potentially important as patients with heart failure after an episode of acute decompensation have been seen to have increased levels of thrombin. No other drug is currently licenced for use in this group of patients which targets thrombin.
Canakinumab (ILARIS®) for Cardiovascular risk reduction – Add on therapy
Cardiovascular disease (CVD) is a general term that refers to all conditions affecting the heart and blood vessels (circulation). These include angina, heart attack (also known as myocardial infarction), heart failure, stroke, and a number of diseases that affect the blood vessels. CVD is usually associated with a build-up of fatty deposits inside the blood …